- Home
- ITGR vs IDYA Comparison
ITGR vs IDYA Comparison
Compare ITGR & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ITGR | IDYA |
|---|---|---|
| Founded | 1970 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.9B |
| IPO Year | 2000 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ITGR | IDYA |
|---|---|---|
| Price | $84.89 | $33.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 16 |
| Target Price | ★ $91.14 | $51.21 |
| AVG Volume (30 Days) | ★ 835.8K | 738.7K |
| Earning Date | 05-18-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.90 |
| EPS | ★ 2.89 | N/A |
| Revenue | ★ $1,853,637,000.00 | $218,710,000.00 |
| Revenue This Year | $1.69 | N/A |
| Revenue Next Year | $6.53 | $213.03 |
| P/E Ratio | $29.97 | ★ N/A |
| Revenue Growth | 7.98 | ★ 3024.43 |
| 52 Week Low | $62.00 | $13.45 |
| 52 Week High | $127.56 | $39.28 |
Technical Indicators
Market Signals| Indicator | ITGR | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 49.52 | 49.19 |
| Support Level | $82.78 | $32.85 |
| Resistance Level | $87.54 | $33.64 |
| Average True Range (ATR) | 2.76 | 1.34 |
| MACD | -0.11 | 0.09 |
| Stochastic Oscillator | 34.57 | 45.77 |
Price Performance
Historical ComparisonAbout ITGR Integer Holdings Corporation
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns maximum of its revenue in the United States, and also has its presence in Ireland, Puerto Rico, Costa Rica, and Rest of the World.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.